11d·
5 sources

Study Reveals Low Rates of Gender-Affirming Medications Among U.S. Adolescents

A new study shows fewer than 1 in 1,000 U.S. adolescents receive gender-affirming treatments, challenging prevalent political narratives.

This story was covered by 5 sources. This shows the distribution of these sources: left-leaning (blue), center (gray), and right-leaning (red).

Health

Mostly Reliable

The underlying sources generally maintain reliability but have, at times, included opinion pieces, propaganda, or minor inaccuracies. While typically factual, there may be occasional editorialization or subjective interpretation.
Balanced

Summary

A summary of the key points of this story, verified by multiple sources.

A recent JAMA Pediatrics study found that fewer than 0.1% of U.S. adolescents with commercial insurance received gender-affirming medications from 2018 to 2022. Analyzing data from over 5 million patients, the study revealed only 926 adolescents were prescribed puberty blockers, and 1,927 received hormones, primarily among assigned female at birth youth. The findings challenge often exaggerated claims about transgender youth healthcare amidst ongoing legal debates and state-level bans. Major medical organizations endorse these treatments as necessary, but access remains limited, prompting calls for a more accurate public understanding of gender-affirming care.

Informed by:

From the Right

A recap of the main views or arguments shared by right-leaning sources.

  • Fewer than 1 in 1,000 U.S. adolescents with commercial insurance received gender-affirming medications, indicating that concerns about extensive use are overstated.

  • At least 26 states have enacted laws restricting gender-affirming medical care for transgender minors, reflecting a growing trend among lawmakers to legislate on this issue.

  • The study published in JAMA Pediatrics suggests that healthcare practitioners are exercising caution when prescribing treatments to adolescents, especially by not prescribing hormones to those under 12.

Informed by:

Highlights (0)

Excerpts from the underlying articles that best reflect each outlet's unique perspective on this story.

No highlights available for this story.